LoadingLoadingLoading43 funds hold it.Insiders net selling.
Net selling: insiders sold $17M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $35K to $99K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Q3 2026
Earnings per share
$6.35 expected
Revenue
$22.62B expected
Full-year 2026 guidance
$91.00B to $92.00B
No comparable estimate
Estimates as of Nov 4, 2026
EPS expected
$10.15 to $12.42
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $7.48est. $6.35 | +17.88%beat | $24.40Best. $22.62B+7.88% | +38.6%from $17.60B |
| Jun 30, 2026Reported Aug 5, 2026 | $8.38est. $6.58 | +27.27%beat | $22.97BSEC filing | +47.7%from $15.56B |
| Mar 31, 2026Reported Apr 30, 2026 | $8.55est. $6.79 | +25.90%beat | $19.80BSEC filing | +55.5%from $12.73B |
| Dec 31, 2025Reported Feb 4, 2026 | $7.54est. $6.91 | +9.14%beat | $19.29BAlpha Vantage | +42.6%from $13.53B |
| Sep 30, 2025Reported Oct 30, 2025 | $7.02est. $5.89 | +19.19%beat | $17.60BSEC filing | +53.9%from $11.44B |
| Jun 30, 2025Reported Aug 7, 2025 | $6.31est. $5.61 | +12.48%beat | $15.56BSEC filing | +37.6%from $11.30B |
| Mar 31, 2025Reported May 1, 2025 | $3.34est. $3.46 | -3.47%miss | $12.73BSEC filing | +45.2%from $8.77B |
| Dec 31, 2024Reported Feb 6, 2025 | $5.32est. $5.07 | +5.00%beat | $13.53BAlpha Vantage | +44.7%from $9.35B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $19.29B | $19.80B | $22.97B | $24.40B |
| Cost of what it sold | $3.37B | $3.58B | $3.27B | $3.93B |
| Gross profit | $15.92B | $16.22B | $19.71B | $20.46B |
| What it spent | ||||
| Research and development | $3.80B | $3.51B | $3.82B | $4.25B |
| Sales and admin | $3.34B | $2.93B | $3.43B | $3.13B |
| Other operating costs | -$212.1M | — | — | $4.48B |
| Total operating expenses | $6.93B | $6.44B | $7.25B | $11.86B |
| What was left | ||||
| Operating profit | $8.99B | $9.78B | $12.46B | $8.61B |
| Interest on debt | $123.0M | $332.0M | $345.0M | $378.0M |
| Profit before tax | $8.27B | $8.85B | $9.25B | $8.41B |
| Tax | $1.63B | $1.45B | $2.15B | $1.96B |
| Net profit | $6.64B | $7.40B | $7.09B | $6.45B |
| EBITDA | $12.14B | $10.29B | $12.99B | $9.33B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.61% on Nov 3: Drivers Behind the Movement
Leans bullishNov 3Pfizer Earnings: Our Pipeline View Is Incrementally Positive
Leans bullishNov 3Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
NeutralNov 3Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
NeutralNov 3Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Leans bullishNov 3Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
BullishNov 3Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Leans bullishNov 3$1B in cash and securities accompanies a wider Q3 loss at Beam Therapeutics (BEAM).
NeutralNov 332 macro signals shaping LLY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
